| 摘要 |
The present invention relates to the use of mimotopes in the treatment of &bgr;-Amyloidoses including but not limited to Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to non truncated A&bgr;1-40/42, and N-terminally truncated forms A&bgr;pE3-40/42, A&bgr;3-40/42, A&bgr;11-40/42, A&bgr;pE11-40/42 and A&bgr;14-40/42 without interfering with physiological functions of APP signalling.
|
